Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Coulter Partners places Chief Executive Officer at Alethio Therapeutics

LONDON, UK  – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.

Ikarovec to Advance Pipeline with Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology

Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology


Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease

Internship - 2026/2027

eg technology are offering a 12-month paid internship for motivated and creative students (completing a “year in industry”) or recent graduates seeking professional experience.

At eg technology, you’ll:

· Work on real, challenging projects across multiple disciplines.

· Gain hands-on experience in your chosen discipline, mechanical engineering, industrial design and software engineering.

· Receive comprehensive mentoring, guidance and feedback to accelerate your skills and knowledge.

BioBiz Buzz EPISODE ALERT: From the Horse’s Mouth — Inside Pharma’s Most Volatile Year with Mike Ward, Clarivate

NEW BioBiz Buzz EPISODE ALERT: “From the Horse’s Mouth — Inside Pharma’s Most Volatile Year”

What a year it’s been. Pharma’s first $1 trillion company. A $400 billion collapse. Mass layoffs, geopolitical upheaval, AI valuations soaring, and a regulatory reset that changes everything for rare disease developers.

Subscribe to